219 related articles for article (PubMed ID: 3124451)
1. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
2. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
5. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
7. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
[TBL] [Abstract][Full Text] [Related]
8. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
9. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
Walewski J; Paietta E; Dutcher J; Wiernik PH
J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
12. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945
[TBL] [Abstract][Full Text] [Related]
15. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
16. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
17. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
18. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Mier JW; Aronson FR; Numerof RP; Vachino G; Atkins MB
Pathol Immunopathol Res; 1988; 7(6):459-76. PubMed ID: 2976936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
